skip to main content, skip to Quick links, or skip to Search

main content


Radiation Therapy for the Management of Cardiac Hemangiosarcoma in Dogs


Hemangiosarcoma (HSA) is a common and devastating disease in dogs; cardiac HSA (CHSA) is a common variant for which accessible treatments are particularly lacking.  Unique vascular biology suggests that high dose single fraction radiation therapy (HDSF RT) should be particularly useful in this disease setting.  The primary goal of the planned pilot study is to determine how the activity of HDSF RT against CHSA is clinically manifested.  To accomplish this, we will randomize dogs to be treated with RT or mock RT (placebo) in a blinded manner, and quantify changes in tumor volume, frequency and timing of recurrent cardiac tamponade (blood on the heart), and overall survival time.  This information will guide use of various outcome measures in future studies.  To that end, we hypothesize that HDSF RT will cause tumor volume and frequency of recurrent tamponade to decrease, and overall survival time to increase as compared with unirradiated control subjects.  Secondary goals of this study are to (1) collect blood samples before and after RT in effort to develop biomarkers of the tumor response to RT into predictive and prognostic assays, and (2) evaluate means for making such RT more widely accessible to veterinary clientele.

Study Procedure and Requirement:


Financial Incentive:


Clinical Studies Core at 919.513.6384 or or NCSU Radiation Oncology Service at 919.513.6690 or


Page last updated December 30, 2013